ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 49

Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis

Charlene Hopper1, Sarah Khan2, Jacqueline Mancini2 and Janet Rennick3,4, 1Rheumatology, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, 2Ingram School of Nursing, McGill University, Montreal, QC, Canada, 3Nursing, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, 4Ingram School of Nursing and Department of Pediatrics, McGill University, Montreal, QC, Canada

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: juvenile idiopathic arthritis (JIA), methotrexate (MTX), qualitative and quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose:  Methotrexate (MTX) remains an effective and commonly used disease modifying anti-rheumatic drug (DMARD) for the treatment of Juvenile Idiopathic Arthritis (JIA). Approximately half of the children taking MTX will experience MTX intolerance, that is nausea, vomiting, anticipatory or associative nausea/vomiting. While we have information about MTX intolerance from the perspective of parents and older children, to date there are no studies focused on school-age children’s perception of MTX intolerance and its impact on daily life. School-age children have decisions made for them, however they remain experts of their own care and their input is essential for collaborative care and management. The purpose of this study was to explore school-age children’s perceptions of MTX intolerance, how MTX intolerance impacts their daily lives and how they manage MTX intolerance.

Methods: An interpretive descriptive design was used with purposive sampling to explore the perceptions of school-age children with JIA experiencing MTX intolerance. All children were interviewed using semi-structured interviews that incorporated a storyboard technique. The storyboard was in the shape of a house with 4 rooms. Children were provided with a variety of felt pieces depicting family members, pets, toys and furniture. Medical play items were also provided, including a syringe, needle, alcohol swab and pill bottle. The storyboard activity allowed the participants to begin to tell their stories about MTX intolerance by visually setting up and displaying their home environment, including the room in which they took their MTX, and to describe who was involved in their MTX administration. The storyboard facilitated the semi-structured interview in which children continued to describe their experience of MTX intolerance. Interview and observational data were collected and analyzed using qualitative inductive content analysis.

Results:  Twelve children, aged 6-12 years participated in the study. Interviews lasted an average of 35 minutes. All children enjoyed using the storyboard. Three themes were identified that captured the children’s experiences: (1) Children’s perceptions of methotrexate intolerance (including descriptions of anticipatory and associative nausea): “No kid likes taking methotrexate”. (2) Children’s strategies for managing MTX administration: ”When I’m going to take my MTX…I’m going down the stairs in slow motion”. (3) Working hard to live with MTX intolerance: “The next day, I’m happy because it’s another week” [before MTX again].

Conclusion: School-age children are able to clearly articulate their experience of MTX intolerance. Findings highlight the importance of exploring young children’s perceptions of intolerance when developing clinical strategies to manage care. Results will be used to explore more effective ways to prevent and manage MTX intolerance.


Disclosure: C. Hopper, None; S. Khan, None; J. Mancini, None; J. Rennick, None.

To cite this abstract in AMA style:

Hopper C, Khan S, Mancini J, Rennick J. Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/perceptions-of-methotrexate-intolerance-in-school-aged-children-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/perceptions-of-methotrexate-intolerance-in-school-aged-children-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology